SEHK:2228Life Sciences
XtalPi Holdings (SEHK:2228) Stock Looks Hard To Justify After New R And D Alliance
XtalPi Holdings (SEHK:2228) has drawn fresh investor attention after announcing a new R&D alliance with a global biopharmaceutical partner to co-develop an oral small molecule therapy targeting a complex GPCR receptor.
See our latest analysis for XtalPi Holdings.
XtalPi Holdings' recent R&D alliance arrives after a weak run in the share price, with the 30 day share price return down 16.33% and the year to date share price return down 33.83%, even as the 1 year total shareholder return is...